2 Min Read
Feb 9 (Reuters) - Regeneron Pharmaceuticals Inc -
* Regeneron CEO: "As we further diversify our product related revenue stream, we do not plan to provide eylea guidance after 2017"
* Regeneron CEO says Amgen's asserted patent claims on repatha are invalid and we look forward to pursuing our appeal over the coming months: conf call
* Regeneron's Bob Terifay says Eylea will continue for co over the years to come
* Regeneron: Eylea sales growth has slowed reflecting normal market dynamics for the product that has been around for over 5 yrs with no price hike since launch
* Regeneron CEO says changes in pharmaceutical drug pricing will need congressional action
* Regeneron CEO "Price increases that are unrelated or uncoupled from innovation will be pushed back on"
* Regeneron CEO: Constant price increases & magnitude of them are reflection of tone deafness on those taking hikes & complexities about how rebates work
* Regeneron CEO: "There is an opportunity to come up with more responsible pricing", in relation to rheumatoid arthritis drug, sarilumab
* Regeneron CEO: "Pharma is running around saying the middleman (PBM) is taking too much; the middleman says prices are too high and patients are wondering what is really going on"
* Regeneron CEO: "price increases are nice but if you cannot get them you better be able to innovate and that is our sweet spot" Further company coverage: